145 related articles for article (PubMed ID: 10220615)
1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
Anderson KM; Bala MV; Weisman HF
Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615
[No Abstract] [Full Text] [Related]
2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
Mark DB; Simons TA
Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
[No Abstract] [Full Text] [Related]
3. Cost and outcomes analysis of abciximab use in a community teaching hospital.
Abernathy GB; Hewitt KK
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S35-7. PubMed ID: 9872696
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
Boersma E
J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
[No Abstract] [Full Text] [Related]
5. [Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature].
Sturm C
Med Klin (Munich); 1996 Nov; 91(11):735-8. PubMed ID: 9036301
[No Abstract] [Full Text] [Related]
6. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
Mayosi BM; Latouf SE; Commerford PJ
S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492
[No Abstract] [Full Text] [Related]
7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
Schrogie JJ
Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614
[No Abstract] [Full Text] [Related]
8. Enthusiasm, reality, and cost-effectiveness analysis.
Brophy JM; Sleight P
Heart; 1998 Jan; 79(1):9-10. PubMed ID: 9505910
[No Abstract] [Full Text] [Related]
9. Abciximab therapy in percutaneous intervention: economic issues in the United States.
Goklaney AK; Murphy JD; Hillegass WB
Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499
[TBL] [Abstract][Full Text] [Related]
10. Murmurs from the heart (or why the stethoscope is not an economic tool).
Aristides M; Gliksman M
Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073
[No Abstract] [Full Text] [Related]
11. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
Oh PI; Cohen EA; Mittmann N; Seung SJ
Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
[TBL] [Abstract][Full Text] [Related]
12. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
[TBL] [Abstract][Full Text] [Related]
13. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
[No Abstract] [Full Text] [Related]
14. Routine use of abciximab in coronary stenting?
Stables RH
Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
[No Abstract] [Full Text] [Related]
15. Using cost-effectiveness for subsidy decisions.
Glasziou P
Heart; 1998 Jan; 79(1):7-8. PubMed ID: 9505908
[No Abstract] [Full Text] [Related]
16. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
van Hout BA; Bowman L; Zelinger DJ; Simoons ML
Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523
[TBL] [Abstract][Full Text] [Related]
17. [An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context].
Lorenzoni R; Mazzotta G; Gensini GF; De Caterina R
G Ital Cardiol; 1999 Mar; 29(3):269-76. PubMed ID: 10231672
[TBL] [Abstract][Full Text] [Related]
18. Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug.
Reed SD; Mullins CD; Roffman DS; Mays DA
Am J Health Syst Pharm; 1998 Nov; 55(22):2409-14. PubMed ID: 9825038
[No Abstract] [Full Text] [Related]
19. [Use of abciximab during coronary angioplasty].
Philippe F; Montalescot G; Drobinski G; Thomas D
Arch Mal Coeur Vaiss; 1997 Dec; 90(12):1645-50. PubMed ID: 9587446
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients.
Aristides M; Gliksman M; Rajan N; Davey P
Heart; 1998 Jan; 79(1):12-7. PubMed ID: 9505912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
